Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
Cymabay Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 19, 2023
Cymabay Therapeutics reported fiscal year 2022 executive compensation information on April 19, 2023.
In 2022, three executives at Cymabay Therapeutics received on average a compensation package of $1.6M, a 11% increase compared to previous year.
Average pay of disclosed executives at Cymabay Therapeutics
Sujal Shah, Chief Executive Officer, received $2.6M in total, which increased by 16% compared to 2021. 59% of Shah's compensation, or $1.5M, was in option awards. Shah also received $450K in non-equity incentive plan, $590K in salary, as well as $3.8K in other compensation.
Charles A. McWherter, President of R&D, received a compensation package of $1.2M, which increased by 8% compared to previous year. 43% of the compensation package, or $525K, was in option awards.
Paul Quinlan, General Counsel, earned $1.1M in 2022, a 67% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 19, 2023.